Last reviewed · How we verify
Loqoa (ESFLURBIPROFEN)
At a glance
| Generic name | ESFLURBIPROFEN |
|---|---|
| Sponsor | Taisho Pharmaceutical Co., Ltd. |
| Target | Prostaglandin G/H synthase 2 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2015 |
Approved indications
- Osteoarthritis
Common side effects
Key clinical trials
- To Evaluate the Adhesion of TK-254RX on Healthy Participants (PHASE1)
- Phase III Trial to Evaluate the Efficacy and Safety in Patients With Ankle Sprains. (PHASE3)
- Phase III Trial to Assess the Safety and Efficacy of TK-254RX in Patients With Contusions (PHASE3)
- To Assess the Effect of the Special Condition on the Pharmacokinetics and Tolerability of the Esflurbiprofen Topical System (EFTS) in Healthy Volunteers. (PHASE1)
- To Assess the Bioavailability of TK-254RX in Comparison with Oral Flurbiprofen Tablets and the Adhesion of TK-254RX in Healthy Subjects (PHASE1)
- Efficacy and Safety of Esflurbiprofen Hydrogel Patch in the Treatment of Local Acute Pain (PHASE2)
- Proof-of-concept Study of NSAID Hydrogel Patch in Treatment of Acute Pain (PHASE2)
- Safety and Efficacy of SFPP in Knee Osteoarthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |